| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $2,342,454 ) |
| | 2024 | 2024 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 004 | 4 | NIH | 7/3/2024 | $1,565,481 |
| | 2024 | 2024 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 000 | 3 | NIH | 11/22/2023 | $776,973 |
| | 2024 | 2024 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 001 | 3 | NIH | 2/5/2024 | $0 |
| | 2024 | 2024 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 003 | 3 | NIH | 6/11/2024 | $0 |
| | 2024 | 2021 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 002 | 1 | NIH | 6/11/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,519,733 ) |
| | 2023 | 2023 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44AI179385 | Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | 000 | 1 | NIH | 8/21/2023 | $298,049 |
| | 2023 | 2023 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 001 | 2 | NIH | 4/25/2023 | $1,221,684 |
| | 2023 | 2021 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 000 | 1 | NIH | 4/25/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | 000 | 1 | NIH | 7/6/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $397,959 ) |
| | 2021 | 2021 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | 000 | 1 | NIH | 8/31/2021 | $397,959 |
| | 2021 | 2021 | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. | 81 WALNUT ST | WINCHESTER | MA | 01890-2822 | MIDDLESEX | USA | R44CA265510 | Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | 001 | 1 | NIH | 9/2/2021 | $0 |
|
|
